ReviewMetabolic brain disease2005
Which are the right cells to be used in a bioartificial liver?
Review in Metabolic brain disease, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Therapeutic Effects of Mesenchymal Stem Cells for Patients with Chronic Liver Diseases: Systematic Review and Meta-analysis.Journal of Korean medical science · 2015Pooled it
- The Potential Hepatocyte Differentiation Targets and MSC Proliferation by FH1.Journal of cellular and molecular medicine · 2025Article
- Stem Cell-Based Strategies: The Future Direction of Bioartificial Liver Development.Stem cell reviews and reports · 2024Review
- Changes in the hepatic differentiation potential of human mesenchymal stem cells agedAnnals of translational medicine · 2021Article
- Development of a genetically modified hepatoma cell line with heat-inducible high liver function.Cytotechnology · 2021Article
- Human hepatocellular adenoma as a promising cell source for bioartificial liver systems.Experimental and therapeutic medicine · 2019Article
- Potential for Isolation of Immortalized Hepatocyte Cell Lines by Liver-DirectedStem cells international · 2019Review
- Three-dimensional culture of a genetically modified hepatoma cell line using macroporous gelatin beads.Cytotechnology · 2017Article
- Induction of hepatocyte-like cells from human umbilical cord-derived mesenchymal stem cells by defined microRNAs.Journal of cellular and molecular medicine · 2017Article
- A tryptophan derivative, ITE, enhances liver cell metabolic functions in vitro.International journal of molecular medicine · 2017Article
- Cell sources, liver support systems and liver tissue engineering: alternatives to liver transplantation.International journal of stem cells · 2015Review
- Development and characterization of a new human hepatic cell line.EXCLI journal · 2015Article
- Immortalized Human Hepatic Cell Lines for In Vitro Testing and Research Purposes.Methods in molecular biology (Clifton, N.J.) · 2015Article
- Hybrid bioartificial liver support in cynomolgus monkeys with D-galactosamine-induced acute liver failure.World journal of gastroenterology · 2014Article
- Strategies for immortalization of primary hepatocytes.Journal of hepatology · 2014Review
- Microbiological safety of a novel bio-artificial liver support system based on porcine hepatocytes: a experimental study.European journal of medical research · 2012Article
- The establishment and characterization of immortal hepatocyte cell lines from a mouse liver injury model.In vitro cellular & developmental biology. Animal · 2011Article
- Influence of chitosan nanofiber scaffold on porcine endogenous retroviral expression and infectivity in pig hepatocytes.World journal of gastroenterology · 2011Article
- Bioartificial liver devices: Perspectives on the state of the art.Frontiers of medicine · 2011Review
- Feeder-independent continuous culture of the PICM-19 pig liver stem cell line.In vitro cellular & developmental biology. Animal · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Anno 2004 freshly isolated or cryopreserved porcine or human hepatocytes have been most frequently used as bio-component in clinically applied bioartificial livers (BALs). Phase 1 studies of all bio-component modalities showed safety, feasibility, and improvement of biochemical, neurological, and hemodynamic parameters. However, both the pilot-controlled clinical trial with C3A cells and the randomized larger clinical trial with cryopreserved porcine hepatocytes did not show significant improvement of survival by intention-to-treat analysis. Because of the xenotransplantation-related disadvantages of porcine cells and the shortage of primary human hepatocytes, other sources of bio-components have to be explored. The future lies in the development of one or more human hepatocyte cell lines, which will have minimal immunogenicity, no risk of xeno-zoonosis, and the requested functionality and availability. Primary sources for the development of such human cell lines are liver-tumor-derived cell lines, immortalized fetal or adult hepatocytes, and stem cells of hepatic, hematopoietic, or embryonic origin. At present the most promising results for BAL application have been obtained by immortalization of human fetal liver cells by reconstitution of telomerase activity. However, in all cell types tested so far, the in vitro differentiation cannot be stimulated to such an extent that their functionality reaches that of primary human hepatocytes. More insight in differentiation-promoting factors and the influence of matrix and co-culture conditions is needed.
Indexed as
Identifiers
16382343What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.